- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.16 Å
- Oligo State
- monomer
- Ligands
- 14 x SO4: SULFATE ION(Non-functional Binders)
- 1 x 01: ~{N}-[2-[4-[[4-(2-ethanoyl-5-fluoranyl-1~{H}-indol-3-yl)-1,2,3-triazol-1-yl]methyl]piperidin-1-yl]ethyl]-4-(2-fluoranyl-6-oxidanyl-phenyl)benzenesulfonamide
01.3: 33 residues within 4Å:- Chain A: L.67, G.68, R.69, G.70, S.73, V.75, V.88, K.90, I.117, F.135, E.136, H.137, V.138, N.140, F.143, L.146, Y.147, L.150, I.155, Y.158, M.159, P.181, H.182, V.184, M.185, I.186, I.196, D.197, M.243, L.244, M.247
- Ligands: SO4.6, SO4.13
15 PLIP interactions:15 interactions with chain A- Hydrophobic interactions: A:V.75, A:V.75, A:V.88, A:K.90, A:I.117, A:F.135, A:V.184, A:I.186, A:I.196, A:D.197, A:M.247
- Hydrogen bonds: A:N.140, A:V.184, A:I.186
- Water bridges: A:D.197
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Marlhoux, L. et al., Discovery of KDX1381, a Bivalent CK2 alpha Inhibitor for the Treatment of Solid Tumors as a Single Agent or in Combination. J.Med.Chem. (2025)
- Release Date
- 2025-07-30
- Peptides
- Casein kinase II subunit alpha: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.16 Å
- Oligo State
- monomer
- Ligands
- 14 x SO4: SULFATE ION(Non-functional Binders)
- 1 x 01: ~{N}-[2-[4-[[4-(2-ethanoyl-5-fluoranyl-1~{H}-indol-3-yl)-1,2,3-triazol-1-yl]methyl]piperidin-1-yl]ethyl]-4-(2-fluoranyl-6-oxidanyl-phenyl)benzenesulfonamide
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Marlhoux, L. et al., Discovery of KDX1381, a Bivalent CK2 alpha Inhibitor for the Treatment of Solid Tumors as a Single Agent or in Combination. J.Med.Chem. (2025)
- Release Date
- 2025-07-30
- Peptides
- Casein kinase II subunit alpha: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
B